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Abstract: Medulloblastoma, the most common pediatric malignant brain tumor, continues to
have a high rate of morbidity and mortality in childhood. Recent advances in cancer genomics,
single-cell sequencing, and sophisticated tumor models have revolutionized the characterization
and stratification of medulloblastoma. In this review, we discuss heterogeneity associated with four
major subgroups of medulloblastoma (WNT, SHH, Group 3, and Group 4) on the molecular and
cellular levels, including histological features, genetic and epigenetic alterations, proteomic landscape,
cell-of-origin, tumor microenvironment, and therapeutic approaches. The intratumoral molecular
heterogeneity and intertumoral cellular diversity clearly underlie the divergent biology and clinical
behavior of these lesions and highlight the future role of precision treatment in this devastating brain
tumor in children.
Keywords: medulloblastoma; molecular subgroups; genetic and epigenetic heterogeneity;
intertumoral diversity; clinical trials
1. Introduction
Medulloblastoma (MB) is the most common malignant brain tumor of childhood, which is
classified as an embryonal tumor located in the cerebellum. With an incidence rate of 0.156 cases
per 100,000 population, MB ranks second behind leukemia in incidence, but carries a much worse
overall prognosis [1]. Histologically and genomically, MB is a heterogeneous disease that differs greatly
among patients. The histologic classification of MB consists of four types based on morphological
evaluation, including Classic (CLA), desmoplastic/nodular (DN), MB with extensive nodularity
(MBEN), and large cell/anaplastic (LCA) [2]. Of these findings, moderate to extensive anaplasia, along
with presence of metastases, were characterized with having the worse prognosis [3,4]. Given that
histological classifications can only partially reflect disease heterogeneity and insufficiently predict
patient outcome, MB has since become subclassified on key molecular variations in addition to their
histological characterization.
Multiple studies using genetic and transcriptional profiling of MB samples identified four distinct
molecular subgroups: wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4 [5–10]. Each of
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these subgroups has different molecular drivers, clinical characteristics, and prognoses; for example,
the SHH tumors, especially those tumors with TP53 mutations, and Group 3 have the worse prognosis
while the WNT driven MBs are associated with better prognosis [11,12]. Due to the differences in
aggressiveness between the groups, the WNT-driven MB may be treated less aggressively than those
with SHH or Group 3 tumors. This is important as the standard of care use of radiation therapy carries
significant comorbidities, such as developmental delays or secondary cancers that can occur later in
life [13–15]. This makes molecular classification of MBs, especially at initial diagnosis, an imperative.
Therefore, the revised 2016 World Health Organization (WHO) classification requires both histological
and genetical evaluation as a standard diagnosis for MB [16].
Recently, single-cell RNA sequencing (scRNA-seq) based studies provided new insights on
molecular and cellular heterogeneity, which underlie the divergent biology and clinical behavior in
MB [17–19]. This review is meant to explore the intratumoral and intertumoral heterogeneity and
diversity that characterize MB, and how the differences between the subgroups could potentially
contribute to the treatment and/or prognosis of affected patients.
2. Molecular Heterogeneity in MB
2.1. Molecular Stratifications of MB
In 2012, researchers reached a consensus that classified MB into four different subgroups based on
their molecular characterization, namely WNT, SHH, Group 3, and Group 4 [10]. Of these subgroups,
WNT and SHH were distinguished by the signaling pathways that contribute to their pathogenesis
while Group 3 and Group 4 are separated based on clustering algorithms rather than a single activated
pathway. WNT and SHH subgroups have a balanced sex ratio, while Group 3 and Group 4 MBs
have a male predominance [10]. It is important to note that these classifications are distinct from the
histological subgroupings, although there is significant overlap (Figure 1). For example, Group 3
MBs generally display a classic phenotype, although with some patients exhibiting anaplastic/large
cells pathology as well [10]. Clinical features in MB subgroups were summarized in Figure 2; cellular,
genetic and molecular characteristics of MB subgroups were described below and summarized in
Table 1.
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Figure 1. Relation of histological types and molecular types. The two columns represent histological 
classification and molecular classification, respectively. Different heights correspond to different 
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the more overlapping patients it has. This figure was made based on the date from the reference [12]. 
CLA: classic medulloblastoma; DN: desmoplastic/nodular medulloblastoma; LCA: large 
cell/anaplastic medulloblastoma; MBEN: medulloblastoma with extensive nodularity. 
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Lines between the columns represent the overlapping classification syste s. The broader a line,
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CLA: classic medulloblastoma; DN: desmoplastic/nodular medulloblastoma; LCA: large cell/anaplastic
medulloblastoma; MBEN: medulloblastoma with extensive nodularity.
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2.1.1. WNT
Of the different subgroups, the WNT MB has the best prognosis and accounts for 10% of all patients
with MB. Patients with WNT MB are expected to have > 90% survival [10,25]. Named by its core
molecular pathway, WNT MB contains frequent mutations in the WNT pathway, including CTNNB1,
deletion of chromosome 6, and strong immunohistochemical nuclear staining for β-catenin [10].
Integrated analysis of gene expression and DNA methylation further defined two WNT subtypes:
WNTα and WNTβ [12]. While WNTα and WNTβ tumors have similar survival, the WNTα subtype is
enriched for children who have the high frequency of monosomy 6 while WNTβ subtype primarily
incorporates older children and adults with a low frequency of monosomy 6 [12].
2.1.2. SHH
SHH MB is the dominant subgroup in both young children (≤3 years old) and adults (≥16 years
old) [26]. This subgroup accounts for about 30% of all patients with MB, and is defined by its activation
or mutation in the SHH signaling pathway, thus giving rise to the SHH nomenclature [27]. SHH
tumors often contain mutations in genes that activate or promote SHH signaling, such as PTCH1,
SMO, SUFU, and amplifications of GLI1 and GLI2 [27,28]. It is thought that overactivation of SHH
pathway is potentially the source of tumorigenesis, as patients with germline mutations in SUFU,
are at increased risk to develop SHH MB in infancy [28,29]. This SHH subgroup carries with it an
intermediate prognosis except in instances where the tumor also harbors TP53 mutations, in which
there is a poorer prognosis [30]. Additionally, infant and adult SHH MBs are distinct both clinically and
molecularly [27]. Clinically, metastasis in adult SHH MBs often portends a poor prognosis, while not in
young children [27]. Desmoplastic SHH MB is a mark of good prognosis in young children, but not in
adults [27]. Cytogenetically, over-representation of chromosome 10q deletion and MYCN amplification
are more significant in young children [27]. Chromosome 10q deletion, 2 gain, 17p deletion, 17q gain,
and/or GLI2 amplification in adults often means a much worse prognosis than in young children [27].
Recently, SHH MB was further classified into four subtypes: SHHα, SHHβ, SHHγ, and SHHδ based
on DNA methylation and gene expression array datasets [12]. SHHα subtype is enriched for children
who have frequent TP53 mutations and MYCN/GLI2 amplifications. SHHβ and SHHγ occur in young
children, whereas SHHβ tumors have a worse overall survival with frequent metastases compared to
SHHγ tumors that are enriched for the MBEN histology. SHHδ tumors primarily occur in adults, have
a favorable prognosis and have a high frequency of TERT promoter mutations.
2.1.3. Group 3
Of the subgroups, Group 3 has the worst prognosis in MB, with a 5-year survival ranging from 39%
to 58%, depending on age of the patient and treatment regimen [26]. One potential reason for the poorer
prognosis is that 50% of patients with Group 3 MB have metastases at the time of diagnosis [31,32].
The most common cytogenetic event in Group 3 is isochromosome 17q (40–50%). Other common
events include loss of chromosomes 8, 10q, and 16q and gain of 1q, 7, and 18 [20]. Currently, there
is no consensus if these tumors are driven by a distinct pathway, however Group 3 tumors contain
recurrent MYC amplifications, GABRA5 overexpression, and SMARCA4 mutations [31]. Due to a lack
of a single unifying mutation or activated pathway, these tumors are often clustered based on their
transcriptional profile rather than a single marker [10,24]. A recent study based on the integrated
analysis of gene expression and DNA methylation defined three subtypes of Group 3 MB: Group
3α, Group 3β, and Group 3γ [12]. Group 3α tumors are enriched for young children, while Group
3β and Group 3γ tumors occur more commonly in older children. Interestingly, Groups 3α and 3β
have a more favorable prognosis compared with Group 3γ, but Group 3α and Group 3γ are more
frequently metastatic compared with Group 3β. Molecularly, chromosome 8q loss is more frequent in
Group 3α and gain more frequent in Group 3γ. Furthermore, MYC amplification is more frequent in
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Group 3γ; Group 3β tumors have a higher frequency of OTX2 gain, DDX31 loss, and high GFI1/GFI1B
expression [12].
2.1.4. Group 4
Group 4 MB is the most common form of MB and accounts for 35–40% of all MBs [10]. Similar to
Group 3, Group 4 MB does not have a unifying molecular signature and instead must be distinguished
based on the overall transcriptional/molecular profile [10]. Genetically and transcriptionally, the highly
prevalent putative driver events in Group 4 involve overexpression of PRDM6 (17%) and GFI1/GFI1B
(5–10%), somatic mutations of KDM6A (9% ), ZMYM3 (6%), KMT2C (6%) and KBTBD4 (6%),
and amplifications of MYCN (6%), OTX2 (6%), and CDK6 (6%) [20]. Cytogenetically, Group 4
tumors have the most common aberration with isochromosome 17q (80%) and other less frequent
aberrations including gain of chromosomes 7 and 18q, and loss of 8q, 8p, 11p, and X [10,20]. Recently,
three subtypes of Group 4 tumors were defined as Group 4α, Group 4β and Group 4γ [12]. Clinically,
there is no statistically significant difference in the overall survival and metastasis rate at diagnosis
between these groups. Molecular features associated with these three subtypes include MYCN and
CDK6 amplification in group 4α, SNCAIP duplication in group 4β, and CDK6 amplification in group
4γ [12].
2.2. Epigenetic Regulation in MB Subgroups
Epigenetic regulation plays an important role in MB development, which mainly includes
DNA methylation, histone modifications, ATP-dependent chromatin remodeling, and genomic
structural variations. Importantly, epigenetic regulators serve as oncogenes or tumor suppressors in a
context-dependent manner across the distinct subtype of MB [33–35].
2.2.1. DNA Methylation
DNA methylation is a well-characterized epigenetic mechanism, typically occurring on CpG
islands of gene promoter regions, resulting in transcriptional repression during normal development
and tumorigenesis [36]. Based on whole genome bisulfite sequencing on 230 MB samples,
Schwalbe et al. previously demonstrated that subgroups classified by DNA methylation status
are highly related to their transcriptomic counterparts, indicating heterogeneity of DNA methylation
associated with distinct molecular, clinical and pathological disease characteristics in MB [37].
Mechanistically, in contrast to the classical notion of gene repression though promoter hypermethylation,
a comprehensive analysis by combining whole-genome, RNA, chromatin immunoprecipitation (ChIP)
and whole-genome bisulphite sequencing data revealed that hypomethylation of non-promoter regions
correlates with increased gene expression in MB subgroups [38]. For example, the low-risk Group
3 MB was defined primarily by hypermethylation with respect to normal cerebellum, whereas the
high-risk Group 3 MB was defined by hypomethylation [39]. These studies further demonstrated
complexity and diversity of DNA methylation features in MB subgroups.
2.2.2. Histone Modifications
Histone modifications play a crucial role in controlling chromatin structure and gene transcription,
which include histone methylation, phosphorylation, acetylation, and ubiquitination. Genomics
studies of MB provided strong evidence that alterations of histone modifiers result in deregulating
the epigenetic machinery, particularly in modifications of lysine methylation and/or acetylation,
which fundamentally contributes to MB development in the distinct subgroups [20,40,41]. Specifically,
frequent mutations of MLL2/KMT2D and MLL3/KMT2C, two histone-lysine N-methyltransferases that
regulate H3K4 methylation, were identified in 16% of MB [41]. Interestingly, MLL2 mutations were
slightly enriched in WNT and SHH subgroups, while MLL3 were found only in Group 3 and Group 4
MBs [41,42]. In contrast, KDM6A/UTX, a H3K27me demethylase binding to MLL2/3 complex, is the
most frequently mutated gene and co-occurs with ZMYM3 mutations in Group 4 MBs [42–44]. However,
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EZH2, the major subunit of the H3K27 methyltransferase PRC2 complex, was identified to be highly
expressed in Group 3 and Group 4 MBs with globally elevated H3K27me3 levels and a worse prognosis
compared with WNT and SHH MBs [34,44]. In addition to histone methylation, histone acetylation also
plays many fundamental and context-dependent roles in MB. Gene mutations of CREBBP and EP300,
encoding histone acetyltransferases (HATs) CBP and p300 respectively, were found in MB [44–46];
these HATs catalyze H3K27ac, an active enhancer mark associated with the higher activation of
gene transcription [47]. Based on high-resolution chromatin immunoprecipitation with sequencing
(ChIP-seq) for active enhancers (H3K27ac) in tumor samples and cell lines, Lin and colleagues found
subtype-specific super-enhancers in MB transcriptional diversity [48]. These super-enhancers regulate
ALK in WNT, SMO and NTRK3 in SHH, LMO1, LMO2 and MYC in Group 3, and ETV4 and PAX5 in
Group 4 MBs [48]. Another class of histone modifier, the Bromodomain and Extra-Terminal Domain
(BET) family proteins (BRD2, BRD3, BRD4), recognize acetylated lysine residues on euchromatin and
promote transcription, epigenetically regulate MYC expression in Group 3 MB, suggesting therapeutic
potential for this subgroup by using BET inhibitors (e.g., JQ1) [44,49,50]. In contrast, genes encoding
subunits of a nuclear receptor corepressor (N-CoR) complex, e.g., GPS2, BCOR and LDB1, which is
associated with histone deactylases (HDACs), are frequently mutated and active in SHH MB, suggesting
effective response of HDACs inhibitors in the treatment of this subgroup tumors [46,47].
2.2.3. ATP-Dependent Chromatin Remodeling
ATP-dependent chromatin remodeling complexes, such as switch/sucrose non-fermentable
(SWI/SNF) and chromodomain helicase DNA-binding (CHD), can utilize the energy from ATP
hydrolysis to reorganize chromatin structure for regulation of gene expression. Recurrent mutations in
SWI/SNF family members including SMARCA4/BRG1 are the most common in WNT and Group 3 MBs
than those in SHH and Group 4 MBs [41,42,44]. Of interest, SWI/SNF complex has both antagonistic
and synergistic roles with PRC1 and PCR2 in context-specific conditions [51–53], indicting significant
contribution of chromatin remodeling in MB biology and treatment. Additionally, ATP-dependent
chromatin remodeling enzyme CHD7 is frequently mutated in Group 3 and Group 4 MBs [44]. Tumors
with CHD7 mutations have reduced EZH2 expression levels [44], further supporting an antagonistic
relationship between SWI/SNF and PCR2 complexes in these subgroups of MB.
2.2.4. Genomic Structural Variations
Structural variations (SVs), including all structural and quantitative chromosomal rearrangements,
not only contribute to the genetic diversity of the human genome, but also modulate basic mechanisms
of gene regulation by altering higher-order chromatin organization [54]. Importantly, Northcott
and colleagues identified diverse SV classes associated with oncogenic activation of GFI1B or its
paralogue GFI1 in Group 3 and Group 4 MBs [22]. Interestingly, the high diversity of SVs affects the
GFI1B and GFI1 locus or surrounding genomic regions, including deletions, inversions, duplications,
and interchromosomal translocations. Topologically, these SVs juxtapose GFI1 or GFI1B coding
sequences proximal to active enhancer elements, including super-enhancers, resulting in transcriptional
activation of these oncogenes and malignant transformation in Group 3 and Group 4 MBs [22].
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2.3. Proteomics in MB Subgroups
Genomic characterization of MB has identified the genetic and epigenetic heterogenicity but
struggles to define functional biological processes involved in tumorigenesis. Proteomic and
phosphoproteomic analysis could provide insight into discovering active oncogenic signaling pathways
and mechanisms in MB. Using quantitative (phospho)-proteomics, Forget et al. defined highly divergent
posttranscriptional pathway regulation in MB subgroups in a total of 41 flash-frozen primary MB
tumors, particularly in Group 3 and Group 4 MBs [58]. Specifically, this study further validated aberrant
ERBB4-SRC oncogenic signaling in Group 4, indicating potential therapeutic vulnerability by using
SRC kinase inhibitors in this subgroup of MB [58]. Another study of integrated RNA expression, DNA
methylation and global proteomes/phospho-proteomes of 45 MB samples identified two subsets of
tumors, SHHa and SHHb, suggesting a post-transcriptional heterogeneity within SHH MB. The SHHa
subset has higher levels of proteins associated with mRNA processing, splicing, and transcription,
MYC pathway activation, chromatin remodeling, and DNA repair; while the higher levels of proteins
in the SHHb subset are linked to neuronal and neurotransmitter-like activity, glutamatergic synaptic
pathway, and MAPK/ERK signaling [59]. Interestingly, in this study, post-translational modifications
of MYC (phosphorylation of residues S62 and T58 of MYC) in Group 3 tumors were defined as a higher
risk factor for prediction of patient outcome. This study further reported that different kinase activities
are associated with distinct subtypes of MB, including enrichment of PRKDC phosphorylation in
MYC-activated MB, highlighting PRKDC inhibitors in sensitizing this subset of tumors to radiation [59].
3. Cellular Heterogeneity in MB
3.1. Histological Diversity of MB
The four main histologic types of MB (CLA, DN, MBEN, and LCA) recognized by the WHO are
characterized based on their histological morphology, with separations made on the grade of nodularity,
desmoplasia, and anaplasia [2,3,60]. Of these subtypes, the majority of MBs are characterized as CLA,
which contains small basophilic cells with a high nuclear to cytoplasm ratio. Generally, this pattern is
Cancers 2020, 12, 643 8 of 18
characterized by a high mitotic index as well as apoptotic activity. DN tumors are densely packed
with cells and hyperchromatic nuclei, in addition to collagen layers stratified throughout the tumor.
MBEN tumors are similar to the DN subgroup; however, portions of the tumor lack the collagen zones.
LCA tumors contain high numbers of mitotic and apoptotic cells, and an altered cellular morphology.
However, the anaplastic MB tends to have elevated nuclear pleomorphisms while large cell MB is
characterized by large circular cells with prominent nuclei [60].
3.2. Cell of Origins in MB Subgroups
Although MBs are thought to originate from primitive and undeveloped cells in the brain,
the cell of origin for MB subgroups remains controversial. Most recently, three single-cell RNA
sequencing (scRNA-seq) studies have provided a clearer picture of MB putative subtype-specific
origins, highlighting the molecular and cellular diversity of MB across all subgroups, with the potential
insights into understanding of tumor development and treatment response [17–19].
Based on investigation of associations between genotype and MB cell type, Gibson et al. discovered
that WNT MBs arise outside the cerebellum from the lower rhombic lip (LRL) and embryonic
dorsal brainstem, whereas SHH MBs are thought to originate from the cerebellar hemispheres [61].
Furthermore, genetically engineered mouse model studies demonstrated that SHH MBs arise from
cerebellar granule neuron progenitors (GNPs) [62,63]. By single-cell transcriptomics of SHH mouse
models, OLIG2+ glial lineage progenitors were identified to play a pivotal role in tumor initiation,
therapy-resistance and recurrence [19]. Interestingly, SHH MBs in infants (≤3 years old) and adults
(≥16 years old) are thought to originate from different GNP populations. Infant SHH MBs are correlated
with intermediate and mature granule neurons, while adult SHH MBs are correlated with GNPs and
mixed unipolar brush cells (UBCs) and GNPs [17]. In contrast to WNT and SHH MBs, cellular origins
of Group 3 and Group 4 MB remain unclear. Recent scRNA-seq studies uncovered a distinct cellular
hierarchy from undifferentiated to differentiated neuronal linkage in MB subgroups, particularly in
Group 3 and Group 4 tumors [17,18]. Group 3 MBs are dominated by an undifferentiated progenitor-like
program and thought to arise from Nestin+ stem cells, which give rise to a variety of differentiated
progeny including GNPs and UBCs [17,18]. In contrast, Group 4 MBs are dominated by a differentiated
neuronal-like program and associated with neuronal cell fates in the embryonic upper rhombic lip
(URL), including UBCs and glutamatergic cerebellar nuclei (GluCN) as candidate cells-of-origin
for this subgroup [17,18]. As for Group 3 and Group 4 tumors exhibiting overlapping molecular
signatures, a subset of ‘intermediate’ tumors (Group 3/4) are mixed, containing both undifferentiated
and more differentiated populations [17]. Together, these studies provided a clear landscape of MB
subtype-specific cell-of-origin during cerebellar development (Figure 3), further supporting cellular
and developmental diversity in MB biology and providing a proximate explanation for the peak
incidence of MBs in childhood. It would be interesting to understand whether the originating cells
(e.g., NSCs, UBCs, GNPs) are preferentially nourished in these anatomic niches for the development of
each subgroup-specific MB in future research directions.
Cancers 2020, 12, 643 9 of 18Cancers 2020, 12, x FOR PEER REVIEW 9 of 20 
 
Figure 3. Distinct subtypes of MB originate from different progenitor cells and developmental stages. 
The dotted arrow represents developmental process, while the solid arrow represents tumorigenic 
process. Cells with same color have the same origination. This figure was made based on data from 
the references [17,18]. 
3.3. Diversity of Tumor Microenvironment in MB 
The tumor microenvironment (TME) plays an important role in terms of tumor progression, 
evolution, and overall prognosis. TME encompasses the various signaling molecules, supporting cells, 
immune system cells, blood vessels, extracellular matrices, and nutrients that contribute to tumor 
progression and therapy response [64,65]. Emerging evidence based on preclinical MB models and 
bioinformatic analyses of clinical MB samples indicates significant TME heterogeneity across 
different MB subgroups [66–69]. 
The blood–brain barrier (BBB), an anatomic structure consisting of a variety of cell types 
including endothelial cells (ECs), astrocytes and pericytes, is also an important factor in maintaining 
TME. Of interest, there is often a functional BBB that prevents the tumor from being exposed to 
potential chemotherapies found in the blood stream. However, WNT MB, compared to other MB 
subgroups, was identified to have a paucity of functional BBB, making this subset of tumors 
potentially more susceptible to chemotherapies that may not cross the BBB [67]. Mechanistically, 
Wnt/β-catenin signaling being a necessary pathway for BBB formation is thought to be inactive in 
tumor surrounding ECs in WNT MB [67,70]. 
Infiltration of various immune cells in TME is of great interest because these infiltrating 
leukocytes either interfere with tumor progression or promote tumor growth, underlying response 
and efficacy of immunotherapy. Recent studies based on the quantification of gene expression 
signatures uncovered dramatical diversity of immune TME among the MB subgroups [68,69]. Of 
interest, SHH MB, but not Group 3 MB, displays strong signatures of macrophages and T cells, while 
Group 3 MB is enriched with the highest number of CD8+ T cells; PD-L1 expression is highest in WNT 
and SHH MBs, but lowest in Group 4 MB; Group 3 and Group 4 MBs have the largest number of 
cytotoxic lymphocytes and ECs [68]. Importantly, the study of murine SHH and Group 3 MB models 
further confirmed significantly higher percentages of infiltrating immune cells including tumor-
associated macrophages (TAMs) in SHH tumors compared with Group 3 tumors; however, Group 3 
tumors were enriched with more PD-1+ CD8+ T cells, resulting in a survival benefit in the Group 3 
animals only after the treatment with PD-L1 and CTLA4 inhibitors [66]. Therefore, these TME 
characteristics provide promising potential of immunotherapy for treating MB. Several clinical trials 
have been conducting by using immune checkpoint blockade and chimeric antigen receptor T (CAR-
Figure 3. Distinct subtypes of MB originate from different progenitor cells and developmental stages.
The dotted arrow represents developmental process, while the solid arrow represents tumorigenic
process. Cells with same color have the same origination. This figure was made based on data from the
references [17,18].
3.3. Diversity of Tumor Microenvironment in MB
The tumor microenvironment (TME) plays an important role in terms of tumor progression,
evolution, and overall prognosis. TME encompasses the various signaling molecules, supporting cells,
immune system cells, blood vessels, extracellular matrices, and nutrients that contribute to tumor
progression and therapy response [64,65]. Emerging evidence based on preclinical MB models and
bioinformatic analyses of clinical MB samples indicates significant TME heterogeneity across different
MB subgroups [66–69].
The blood–brain barrier (BBB), an anatomic structure consisting of a variety of cell types including
endothelial cells (ECs), astrocytes and pericytes, is also an important factor in maintaining TME.
Of interest, there is often a functional BBB that prevents the tumor from being exposed to potential
chemotherapies found in the blood stream. However, WNT MB, compared to other MB subgroups,
was identified to have a paucity of functional BBB, aking this subset of tumors potentially more
susceptible to chemotherapies that may not cross the BBB [67]. Mechanistically, Wnt/β-catenin signaling
being a necessary pathway for BBB formation is thought to be inactive in tumor surrounding ECs in
NT MB [67,70].
Infiltration of various immune cells in TME is of great interest because these infiltrating leukocytes
either interfere with tumor progression or promote tumor growth, underlying response and efficacy of
immunotherapy. Recent studies based on the quantification of gene expression signatures uncovered
dramatical diversity of immune TME among the MB subgroups [68,69]. Of interest, SHH MB, but not
Group 3 MB, displays strong signatures of macrophages and T cells, while Group 3 MB is enriched with
the highest number of CD8+ T cells; PD-L1 expression is highest in WNT and SHH MBs, but lowest in
roup 4 MB; Group 3 and Group 4 MBs have the largest number of cytotoxic lymphocytes and ECs [68].
Importantly, the study of murine SHH and Group 3 MB models further confirmed significantly higher
percentages of infiltrating immune cells including tumor-associated macrophages (TAMs) in SHH
tumors compared with Group 3 tumors; however, Group 3 tumors were enriched with more PD-1+
CD8+ T cells, resulting in a survival benefit in the Group 3 animals only after the treatment with
PD-L1 and CTLA4 inhibitors [66]. Therefore, these TME characteristics provide promising potential
of i munotherapy for treating MB. Several clinical trials have been conducting by using immune
checkpoint blockade and chimeric antigen receptor T (CAR-T) cell therapies as well as therapeutic
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vaccines [71]. Nonetheless, it would be essential to integrate molecular and immune classification of
MB for guiding future precision immunotherapy.
4. Diagnosis, Current Therapies and Clinical Trials for MB Subgroups
4.1. Diagnosis of MB Subgroups
Clinically, a physical examination aligning with neuroimaging, biopsy, and cerebrospinal
fluid tests is in general being used for MB diagnosis. In 2016, the World Health Organization
(WHO) classification of the Central Nervous System (CNS) tumors initiated an integrative
approach including molecular parameters in combination with histology for MB diagnoses [16].
Given the many possible histological-molecular combinations, the 2016 CNS WHO presented
5 genetic variants (WNT-activated, SHH-activated/TP53-mutant, SHH-activated/TP53-wildtype,
non-WNT/non-SHH/Group 3, and non-WNT/non-SHH/Group 4) in addition to the long-established
histological variants (CLA, DN, MBEN, and LCA) [16]. This diagnoses approach allows greater
flexibility for clinical pathologists with the ability to undertake practical methods in molecular
classification. A previous study reported a NanoString 22-gene signature based on mRNA expression
to stratify molecular subgroups of MB [23]. Furthermore, Gómez et al. reported a novel method for
clinically applicable classification of MB based on DNA methylation detection of tumor samples [24].
Besides molecular subgrouping of MB using gene transcription and DNA methylation features,
magnetic resonance imaging-based radiomic approach is a powerful tool for rapid diagnosis of MB
molecular subgroups in clinic [55,72]. In addition, patient risk stratification in MB subgroups, based
on age, metastatic stage, genetic and cytogenetic alterations, should be considered in diagnosis due
to its significance for prognosis and treatment modalities, which was summarized in Table 2. Thus,
practical and reliable biomarkers for risk stratification are important in MB diagnosis because molecular
heterogeneity leads to prognostic variables in the distinct subgroups and even in the same subgroups
of MB (Table 2). To this end, Shih et al. identified a small panel of cytogenetic biomarkers (GLI2,
MYC, chr11, chr14, 17p, and 17q) to distinguish high-risk and low-risk patients with SHH, Group 3,
and Group 4 MBs, which may provide an excellent tool in patient selection for precision therapy [73].
Table 2. Risk stratification of MB subgroups.











































This table was made based on data from the following references [11,21,39,74].
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4.2. Current Therapies
The therapies for MB treatment are currently based on the patient’s risk factors, and consist of
surgery, radiotherapy (RT), and chemotherapy (CT) [31,75]. Although maximal safe resection is the
first-line treatment for MB, the prognostic benefit of increased extent of resection is attenuated when
molecular subgroup affiliation is taken into account [76]. In a retrospective study, patients with Group
4 MB, especially those with metastatic tumor, showed the progression-free survival (PFS) benefit from
gross total resection (GTR) compared to sub-total resection (STR), while this phenomenon was not
observed in WNT, SHH, and Group 3 MBs [76]. However, overall survival (OS) benefit from GTR vs.
STR was not observed in all subgroups of MB [76].
Craniospinal irradiation (CSI) is usually a follow-up treatment after surgery for children older
than age 3 years. Based on patient risk, the treatment dose is 23.4 Gray (Gy) for standard-risk
patients and 36–39 Gy for high-risk patients [77–81]. After the radiation, patients (>3 years of
age) receive chemotherapeutic agents include vincristine, cisplatin, cyclophosphamide, lomustine,
etoposide, and methotrexate [82]. For young children (<3 years of age), multi-agent chemotherapy and
autologous stem cell transplantation are considered to avoid severe long-term cognitive effects from
radiation [82,83]. Despite the current standard of care improves survival rates, iatrogenic morbidity
and late effects often occur in children who survive MB. Therefore, new therapeutic approaches
based on molecular classification must be developed to reduce these side effects for children with this
brain tumor.
4.3. Clinical Trials
With increasing knowledge in MB genomics and biology, precision medicine is an emerging
approach to clinical care that takes into account tumor genetic make-up and individual variations.
Based on molecular classification of MB, we summarized the completed and ongoing clinical trials in
Table 3. Current clinical trials in WNT MB are focused on decreasing the doses of RT and CT, rather
than targeting WNT signaling, because this subgroup of tumor has a more permeable BBB caused by
the dysfunctional WNT signaling pathway, which enables better penetration of CT molecules into
cancer cells. In addition, restoration of WNT signaling activity can attenuate CT sensitivity [67,81].
There are several trials in progress and completion including lower doses of RT+CT (NCT02066220,
NCT01878617, and NCT02724579) and CT-only tests (NCT02212574).
SHH MB with recurrent mutations in PTCH1 or SMO can benefit from SMO inhibitor,
vismodegib [84,85]. However, high-risk SHH patients harboring SUFU mutation, MYCN and GLI2
amplifications, may not benefit from vismodegib treatment, and patients may also develop irreversible
growth plate fusions after vismodegib treatment, which all limit widespread clinical application [86–89].
Therefore, there is a pressing need for new therapeutic strategies for the highest-risk groups of SHH
patients. The completed and ongoing clinical trials include evaluating vismodegib alone in children and
adults with refractory or recurrent SHH MB (NCT00939484, NCT01239316), oral LDE225 (Sonidegib)
in relapsed SHH MB, and vismodegib in combination with temozolomide in SHH MB. Other clinical
trials are ongoing, including testing CX-4945 drug (silmitasertib sodium), an orally bioavailable, highly
selective and potent CK2 inhibitor, in children with recurrent SHH (NCT03904862), and fimepinostat,
a synthetic, orally-available, small molecule that potently inhibits the activity of HDAC and PI3 kinase
enzymes in recurrent medulloblastoma (NCT03893487). In addition, one open trial aims to assess
the combination of ribociclib and sonidegib on patients with refractory or recurrent SHH at St. Jude
Children’s Research Hospital (SJDAWN).
Group 3 and Group 4 MBs have heterogenous clinical characteristics and outcomes associated
with MYC or MYCN amplification, metastasis, and young age (<3 years of age). A multicenter
clinical trial is ongoing in the comprehensive evaluation of current treatment options by integrating
molecular subgroup and risk stratification status into the trial design (NCT01878617), in which Group
3/Group 4 MBs are prioritized for more rigorous treatment with pemetrexed and gemcitabine [21].
While MYC plays an important oncogenic role in many cancers, it is challenging to be directly targeted
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by small molecules and antibodies due to a lack of an enzymatic active site and its nuclear location [90].
Given that inhibition of BET by small molecule JQ1 resulted in suppressing MYC expression and
thereby induce cell death [50], a pediatric cancer trial is currently underway including assessing
the BET inhibitor BMS-986158 in MB with MYC/MYCN amplification (NCT03936465). Furthermore,
ongoing trials aim to evaluate the inhibition of checkpoint kinases (e.g., CDK4/6, CDK1/2) alone or in
combination with CT drugs in brain tumors including recurrent and refractory SHH, Group 3/Group 4
MBs (NCT02255461, NCT04023669).
Table 3. Clinical trials targeting different medulloblastoma groups.
Conditions Interventions ClinicalTrials.govIdentifier Status





WNT Surgery + Chemotherapy, NoRadiotherapy NCT02212574 Suspended
Targeting SHH pathway Vismodegib (SMO Inhibitor) NCT00939484NCT01239316 Completed
Targeting SHH pathway Vismodegib in combination withTemozolomide NCT01601184 Terminated
Targeting SHH pathway Sonidegib (SMO Inhibitor) NCT01708174 Completed
Targeting SHH pathway CX-4945 (CK2 Inhibitor) NCT03904862 Recruiting
Intensified Treatment of Group
3/Group 4 MB Pemetrexed and Gemcitabine NCT01878617 Recruiting
MYC-driven Group 3 MB BMS-986158(Bromodomain (BRD) andExtra-Terminal Domain (BET) Inhibitor NCT03936465 Recruiting
Group 3 MB PD-0332991/Palbociclib (CDK 4-6Inhibitor) NCT02255461 Terminated
Refractory or Recurrent Group
3/Group 4 MB
Prexasertib (CHK1/2 Inhibitor) and
Gemcitabine NCT04023669 Recruiting
Refractory or Recurrent SHH,
Group 3/Group 4 MB
Prexasertib (CHK1/2 Inhibitor) and
Cyclophosphamide NCT04023669 Recruiting
Recurrent MB Fimepinostat (HDAC and PI3K inhibitor) NCT03893487 Recruiting
Refractory or Recurrent SHH MB Ribociclib and Sonidegib SJDAWN Recruiting
5. Conclusions
Recent advances in cancer genomics, single-cell sequencing, and sophisticated tumor models
have revolutionized our understanding of the biology of MB. It is becoming increasingly clear that
MB is a heterogeneous disease with a high degree of diversity on various molecular and cellular
levels. Four major subgroups of MB (WNT, SHH, Group 3, and Group 4) display tremendous
subtype-specificity in genetic and epigenetic alterations, proteomic landscape, cell-of-origin, tumor
microenvironment, current therapies, and clinical trial design. Undoubtedly, these findings shed
unprecedented light on the development of tailored treatment for children with MB. However,
the side effects of current therapies are still a major obstacle to successful MB treatment. In the
future, greater emphasis needs to be placed on the molecular characterization of MB in the clinic,
as identification of the individual subgroups at diagnosis could help shape the treatment and care of
the patients, and potentially improve the overall survival. Furthermore, as further elucidation of the
activated pathways becomes known, precise and effective therapies targeting the driver mutations in
subtype-specificity can be made available to the patients with this devastating brain tumor in children.
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